Claims
A claim is one precise sentence backed by the literature, for example “removing senescent cells extends the life of mice”. Each one is linked to the articles that support or contradict it.
- Somatic mutations build up steadily with age in virtually all normal tissues, including in cells that do not divide.
- Neurons accumulate mutations with age, faster in neurodegeneration.
- Across 16 mammals, the yearly somatic mutation rate is inversely proportional to lifespan: at the end of life, all carry a similar number of mutations.
- SIRT6 is more active in long-lived species and improves DNA break repair.
- Raising SIRT6 extends the lifespan of male mice.
- Loss of chromosome Y in blood affects a large share of older men and is associated with higher mortality.
- In mice, loss of chromosome Y in blood causes cardiac fibrosis and heart failure, which suggests a causal role.
- Mice low in BubR1 age prematurely; raising it reduces aneuploidy and cancers and extends healthy lifespan.
- LINE-1 retrotransposons wake up in senescent cells and aged tissues; their DNA in the cytoplasm triggers interferon-type inflammation (cGAS-STING pathway).
- Mice whose POLG enzyme no longer corrects its errors accumulate mitochondrial DNA mutations and age prematurely.
- The role of mitochondrial DNA mutations in normal aging is still debated.
- Progerin, a mutant form of lamin A, deforms the nucleus and causes Hutchinson-Gilford progeria (accelerated aging in children, cardiovascular death around age 14-15).
- A persistent DNA damage response is a major driver of senescence and inflammation.
- Werner syndrome, caused by a defective repair helicase (WRN), brings grey hair, cataracts, diabetes, atherosclerosis and cancers from age 20-30.
- In ERCC1-deficient mice, DNA lesions suppress the GH/IGF-1 axis and switch metabolism into a "survival" mode close to caloric restriction.
- Deleting Ercc1 in immune cells alone is enough to age solid organs in mice.
- Clonal hematopoiesis (CHIP), found in more than 10% of people over 70, raises the risk of blood cancer and overall mortality.
- Clonal hematopoiesis (CHIP) raises cardiovascular risk.
- In mice, Tet2-deficient macrophages speed up atherosclerosis through IL-1β/NLRP3 inflammation.
- Age at menopause is strongly associated with variants in DNA repair genes; changing them in mice alters ovarian reserve.
- Repairing DNA breaks redistributes chromatin proteins and erodes epigenetic information.
- DNA repair (PARP) consumes NAD+ at the expense of sirtuins.
- Colibactin from pks+ E. coli leaves a distinct mutation signature in organoids and human colorectal cancers; the link with normal aging is still indirect.
- Lonafarnib reduces mortality in children with progeria (cohort study); FDA-approved in 2020.
- A single base-editing injection corrects the progeria LMNA mutation in mice and doubles median survival.
- In mice, NAD+ precursors soften age-related declines.
- In humans, nicotinamide riboside (NR) is well tolerated and raises NAD+.
- NMN improves muscle insulin sensitivity in prediabetic women; no proven benefit on DNA repair in humans.
- In an exploratory analysis of the CANTOS trial, canakinumab reduced cardiovascular events in TET2 CHIP carriers (HR 0.38); the interaction was not significant.
- When telomeres get too short or damaged, the cell reads them as a DNA break and stops dividing (senescence) or dies.
- Unrepaired telomeric lesions build up with age even in tissues that do not divide (neurons, muscle), in mice and primates: the hallmark is not only about length.
- In telomerase-deficient mice, p53 represses PGC-1α/β: telomere dysfunction leads to metabolic and mitochondrial dysfunction.
- Telomere length is largely genetic; several loci (including TERT, TERC, OBFC1) influence average white blood cell telomere length.
- Smoking, obesity, chronic stress and inflammation are associated with shorter telomeres, with modest effects and uncertain causation.
- Mutations in telomerase genes cause telomere syndromes: bone marrow failure, pulmonary fibrosis, cirrhosis, early greying, cancers; they appear earlier in each generation.
- Short white blood cell telomeres are associated with a higher risk of coronary heart disease (meta-analysis of 24 studies, ~43,000 people, relative risk ~1.5).
- In Mendelian randomization, genetically longer telomeres raise the risk of several cancers but lower the risk of coronary heart disease and aortic aneurysm.
- In a phase 1-2 trial in patients with telomere syndromes, danazol lengthened telomeres (11 of 12 evaluable patients at 24 months) with blood count responses, but with liver and muscle toxicity.
- TERT gene therapy in adult or old mice extends median lifespan (+24% and +13%) without increasing cancer.
- Reactivating telomerase in mice that lacked it reverses degeneration in several tissues (testes, spleen, gut, brain).
- TA-65, a supposed telomerase activator, has only one uncontrolled human study funded by the manufacturer: no robust evidence on health or lifespan.
- Epigenetic marks drift with age, made worse by DNA damage, and correcting them by partial reprogramming rejuvenates tissues in animals.
- Heterochromatin loss lets LINE-1 elements be expressed, which triggers an inflammatory interferon response.
- Identical twins have almost identical epigenetic profiles when young, which diverge with age and lifestyle: part of the drift is due to chance or environment.
- In "ICE" mice, DNA breaks without mutations are enough to speed up epigenetic and physiological aging; OSK reprogramming reverses it (information theory of aging).
- First-generation epigenetic clocks (Hannum, Horvath) accurately estimate chronological age from DNA methylation, in blood or in all tissues.
- Acceleration of second-generation clocks (PhenoAge, GrimAge) is associated with higher mortality, cardiovascular disease, cancer and cognitive decline.
- DunedinPACE measures the pace of aging from the rate of decline of 19 markers followed over 20 years.
- Accelerated aging syndromes show epigenetic acceleration: Werner syndrome with several clocks; Hutchinson-Gilford progeria with the "skin & blood" clock but not with the 2013 multi-tissue clock.
- According to the "epigenetic clock theory", the clock reflects developmental programs that keep running after maturity.
- In the CALERIE randomized trial (~12% fewer calories over 2 years), caloric restriction slightly slowed DunedinPACE (~2-3%) but not PhenoAge or GrimAge.
- In heterochronic parabiosis, the epigenetic age of the young mouse rises then falls back after separation; in humans, stress (surgery, pregnancy, severe COVID-19) raises it reversibly.
- In progeroid mice, cyclic expression of the 4 Yamanaka factors improves several organs and extends lifespan by about 30%.
- Partial reprogramming (OSK) of retinal neurons restores vision in old or glaucomatous mice and rejuvenates their methylation clock.
- Long-term partial reprogramming in normal mice rejuvenates molecular signatures (skin, kidney) without tumours in the protocol used.
- Full or poorly controlled reprogramming causes teratomas and cancers.
- In an uncontrolled pilot trial (9 men), GH + DHEA + metformin rejuvenated epigenetic age by about 2.5 years in one year; very small sample.
- In a randomized pilot trial (43 men), 8 weeks of diet and lifestyle changes rejuvenated the Horvath clock by about 3 years, a difference not significant at the 5% level.
- With age, the network of about 2,000 proteins that makes, folds, repairs and destroys proteins declines, so toxic aggregates build up.
- Chaperone-mediated autophagy (LAMP2A receptor) declines with age.
- In the C. elegans worm, hundreds of proteins become insoluble with age, even without disease, and the proteome loses its balance.
- Some aggregates (amyloid-beta, tau, alpha-synuclein) convert healthy proteins and spread from cell to cell, which explains how neurodegenerative diseases progress through the brain.
- Boosting HSF-1 extends worm lifespan; lowering it shortens it (insulin/IGF-1 pathway acting through DAF-16 and HSF-1).
- Restoring CMA (LAMP2A) in the liver of old mice reduces the build-up of damaged proteins and improves liver function.
- More than 50 diseases are caused by protein misfolding; mutations that make a protein less stable (APP, PSEN1, TTR) bring the disease on earlier, which shows that aggregation is causal for these diseases.
- Niemann-Pick disease type C illustrates the link between chaperones (HSP70) and lysosomes.
- In old rats, the bacterial amyloid curli speeds up alpha-synuclein aggregation.
- The microbiome worsens motor symptoms in a mouse model of Parkinson.
- In mice, pathological alpha-synuclein injected into the gut reaches the brain through the vagus nerve.
- Tafamidis, which stabilises transthyretin, reduces mortality and cardiovascular hospitalisations in cardiac ATTR amyloidosis (phase 3); approved.
- Patisiran (an RNA interference drug that lowers TTR production) improves neuropathy and quality of life in hereditary ATTR (phase 3); approved.
- A single infusion of NTLA-2001 (CRISPR editing of the TTR gene in the liver) lowers TTR by about 87% at 0.3 mg/kg (phase 1).
- Anti-amyloid antibodies slow decline in early Alzheimer (lecanemab -27% over 18 months; donanemab about one third), with brain swelling and microbleeds (ARIA); approved.
- Arimoclomol, which boosts the chaperone response, slows the progression of Niemann-Pick disease type C (phase 2/3); FDA-approved in 2024.
- AMX0035 slowed functional decline in ALS in phase 2, but phase 3 (PHOENIX) was negative and it was withdrawn from the market in 2024.
- ISRIB, which releases the brake of the integrated stress response, improves memory and reverses age-related memory decline in old mice.
- Macroautophagy falls with age in most tissues; blocking it speeds up degeneration and switching it on extends life in several animal species.
- The TFEB factor drives the making of lysosomes and autophagy.
- With age, expression of ATG genes and TFEB falls, lysosomes clog with lipofuscin and mTORC1 is chronically overactive.
- Rubicon, a brake on autophagy, rises with age in worm, fly and mouse; removing it extends worm and fly lifespan and reduces kidney fibrosis in mice.
- In worms, long-lived mutants (insulin pathway, caloric restriction) lose their longevity when autophagy is blocked.
- Removing Atg5 or Atg7 in mouse neurons causes aggregates and neurodegeneration, even without any mutant protein.
- Raising Atg5 or making Beclin 1 constantly active extends mouse lifespan and delays age-related diseases.
- Mutations in autophagy genes cause or favour human diseases: Parkinson (PINK1, Parkin), ALS, lysosomal diseases, severe neurodegenerative diseases.
- A variant of the autophagy gene ATG16L1 (T300A) is associated with Crohn's disease.
- In Alzheimer model mice, stimulating mitophagy (NAD+, urolithin A) reduces amyloid-beta and tau and restores memory.
- Spermidine induces autophagy by inhibiting the enzyme EP300 (an acetyltransferase).
- In mice, old muscle stem cells lose autophagy and tip into senescence; blood stem cells need autophagy to stay functional.
- Rapamycin extends mouse lifespan even when started late in life.
- In older people, a rapamycin analogue (everolimus) improves vaccine response and TORC1 inhibition reduces infections; small sample sizes.
- In the PEARL trial (1 year, low doses), rapamycin is well tolerated with modest effects on some markers.
- Spermidine extends the lifespan of yeast, worm and fly, and protects the mouse heart.
- In the Bruneck cohort, high dietary spermidine intake is associated with lower mortality.
- In the SmartAge trial (12 months, 100 older adults), spermidine had no effect on memory.
- Urolithin A extends worm lifespan and improves mouse muscle.
- In humans, urolithin A is safe and leaves a mitochondrial signature; over 4 months in 66 older adults, walking distance (primary endpoint) did not improve but muscle endurance did.
- Intermittent fasting and caloric restriction have cardiometabolic benefits in humans; their effect on autophagy is hard to measure directly.
- In mice, exercise-induced autophagy is required for some of its metabolic benefits.
- A single mutated gene (daf-2, the insulin/IGF receptor) doubles the lifespan of the C. elegans worm, through the FOXO factor (DAF-16) that switches on stress-resistance genes.
- IGF-1 receptor variants that lower its activity are more frequent in Ashkenazi centenarians.
- The FOXO3A genotype is one of the most replicated genetic associations with longevity.
- People with Laron syndrome (defective growth hormone receptor, very low IGF-1) develop very little cancer and diabetes.
- mTORC1 senses amino acids, insulin and energy; it stimulates protein and fat synthesis and brakes autophagy.
- Removing S6K1, the effector of mTORC1, extends the lifespan of female mice.
- Rapamycin's side effects on blood sugar come from off-target inhibition of mTORC2, which can be separated from the longevity gain.
- Overexpressing SIRT6 extends the lifespan of male mice.
- In the NHANES cohort, high protein intake at ages 50-65 is associated with higher IGF-1 and more cancer and deaths, with a reversal after 65.
- Reviews of diet and longevity: slowing growth signals (fewer calories, less protein) and switching on maintenance extends life in model species; exercise activates AMPK and PGC-1alpha and restores insulin sensitivity.
- mTOR controls the translation of IL-1alpha and hence the inflammatory secretions of senescent cells (SASP); rapamycin reduces them.
- In the Interventions Testing Program (3 sites), rapamycin started at 20 months extends mouse lifespan by 9% (males) and 14% (females).
- A 3-month course of rapamycin in middle-aged mice increases remaining life expectancy by up to 60%, with a lasting effect.
- In a phase 2 trial (about 218 people aged 65+), 6 weeks of low-dose everolimus raised flu vaccine response by about 20%.
- In a phase 2a trial, low-dose RAD001 + BEZ235 reduced respiratory infections over one year.
- RTB101 was positive in phase 2b, but phase 3 missed its primary endpoint (clinically symptomatic respiratory infections).
- In the PEARL trial (114 people, 5-10 mg/week for 48 weeks), rapamycin was well tolerated with a modest signal in women at 10 mg (lean mass, pain); the compounded form was poorly absorbed.
- Diabetics on metformin show mortality similar to or lower than non-diabetics; observational data with possible biases.
- The TAME trial was designed to test whether metformin delays age-related diseases in humans.
- In a randomized trial in older adults, metformin blunts the mitochondrial gains of exercise training.
- In CALERIE (about 12% fewer calories for 2 years, non-obese adults), caloric restriction improved cardiometabolic risk factors.
- Secondary analyses of CALERIE show a slower pace of aging (DunedinPACE) but little effect on GrimAge-type clocks.
- In rhesus monkeys, caloric restriction reduces age-related diseases and improves survival; the NIA and Wisconsin results have been reconciled.
- Acarbose extends mouse lifespan, especially in males (ITP).
- Rapalogs and selective mTORC1 inhibitors are the main drug routes to target this pathway.
- Mitochondrial by-products (ROS) are useful signals at low dose; only their chronic excess becomes harmful.
- In "mutator" mice whose mitochondrial DNA polymerase (POLG) proofreads poorly, mtDNA mutations build up and the mice age early: hair loss, osteoporosis, anaemia, shorter life.
- In mutator mice, aging goes mainly through cell death (apoptosis), not through excess oxidative stress.
- In older humans, mtDNA mutations are spread as a mosaic: some muscle fibres or neurons lose their respiratory chain and others do not.
- Taking vitamins C and E suppresses the metabolic benefits of exercise (mitohormesis).
- A Cochrane meta-analysis of 78 trials concludes that high-dose beta-carotene, vitamin E and vitamin A slightly increase mortality.
- NAD+ falls with age in several tissues, partly because CD38 on inflammatory immune cells consumes more of it; blocking CD38 keeps NAD+ and mitochondrial function in old mice.
- The cell normally removes worn-out mitochondria through the PINK1/Parkin pathway, whose mutations cause familial forms of Parkinson.
- Damaged mitochondria can release their DNA into the cell, where it is mistaken for a virus and triggers an interferon response through cGAS-STING.
- Muscle oxidative capacity falls by about 8% per decade in humans, with less mtDNA and fewer mitochondrial proteins.
- Faulty mitochondria are enough to induce senescence with a distinct SASP driven by the NAD+/NADH ratio; removing mitochondria from a senescent cell erases much of its phenotype.
- In old mice, restoring NAD+ revives the mitochondrial function of muscle stem cells and slightly extends lifespan.
- High-intensity interval training increases mitochondrial capacity and protein synthesis in older muscle.
- Over 4 months, urolithin A improved muscle endurance and biomarkers in people aged 65-90 and in overweight people aged 40-64.
- Nicotinamide riboside is well tolerated and raises blood NAD+; in older muscle it raises the NAD+ metabolome and lowers inflammatory signals, without bioenergetic gain.
- In mice, NMN dampens age-related physiological decline.
- In a small randomized crossover trial (20 people aged 60-79), MitoQ improved vascular function.
- In a phase 2 trial (25 prediabetic women), NMN improved muscle insulin sensitivity.
- Cultured human cells stop dividing after a finite number of divisions (Hayflick limit).
- Senescence is a lasting stress-triggered arrest of cell division; useful short-term (healing, tumour suppression), it turns harmful when senescent cells build up and are no longer cleared.
- In blood T cells, p16INK4a rises exponentially with age, and with smoking and physical inactivity.
- The SASP is a mix of cytokines (IL-6, IL-8, IL-1alpha), growth factors and matrix-degrading enzymes, driven by NF-kB, the inflammasome and IL-1, and can make neighbouring cells senescent (paracrine senescence).
- Transient senescence helps wounds heal through PDGF-AA.
- Genetically removing p16-positive cells (INK-ATTAC model) delays age-related pathologies in fast-aging mice.
- In normal mice, removing p16-positive cells extends median lifespan by about 25% and protects kidney, heart and fat.
- Transplanting a few senescent cells into a young mouse is enough to cause loss of physical function; in old mice D+Q improves physical function and extends remaining survival by about 36%.
- Senescent cells build up in tissues affected by age-related diseases (fibrosis, osteoarthritis, osteoporosis, atherosclerosis, diabetes, kidney and neurodegenerative diseases).
- Removing senescent cells reduces pulmonary fibrosis in mice.
- Local removal of senescent cells slows post-traumatic osteoarthritis in mice.
- Removing senescent cells prevents age-related bone loss in mice.
- The SenMayo gene set detects senescent cells in gene-expression data and rises with age in several human tissues.
- Mitochondria are required for the senescent phenotype.
- mTOR amplifies the SASP by controlling IL-1alpha translation; rapamycin reduces it.
- Navitoclax rejuvenates old blood stem cells in mice, but is toxic to platelets.
- Dasatinib + quercetin was found by transcriptome analysis of senescent-cell survival pathways.
- In an open phase 1 trial (14 patients with pulmonary fibrosis), D+Q was feasible and improved walking distance and speed, without change in lung function.
- In a phase 1 trial (9 patients with diabetic kidney disease), 3 days of D+Q reduced senescent cells in fat and skin 11 days later: first direct proof in humans.
- In a randomized phase 2 trial (60 postmenopausal women), D+Q had no overall effect on bone, with a modest benefit in women with a high senescent-cell burden.
- In a phase 1 trial (5 people with mild Alzheimer), dasatinib reached the cerebrospinal fluid but quercetin did not; tolerance was acceptable.
- Fisetin is the most potent flavonoid tested as a senolytic and extends mouse lifespan even when started late.
- JAK inhibitors reduce the SASP, frailty and fat dysfunction in old mice.
- CAR-T cells against uPAR remove senescent cells and correct liver fibrosis in mice.
- A vaccine against GPNMB improves age-related phenotypes and extends the life of progeroid mice.
- Reviews of senolytic clinical trials: early human data, mostly small and short.
- Blood stem cells build up mutations; some give a growth advantage, leading to clonal hematopoiesis (CHIP).
- In mice, loss of epigenetic information is enough to speed up aging traits, and it is partly reversible.
- In old blood stem cells, higher Cdc42 activity disorganises the cell; inhibiting it with a drug rejuvenates their function in mice.
- Muscle stem cells of very old mice lose their reversible dormancy and become senescent through p16INK4a; repressing p16 restores their regenerative capacity.
- In the gut, mTORC1 signalling in Paneth cells links stem cell function to calorie intake; caloric restriction boosts intestinal stem cell function.
- Exposing old stem cells to young blood (heterochronic parabiosis) partly restores muscle and liver stem cell activity, while old blood inhibits it.
- Removing senescent cells with ABT263 (navitoclax) rejuvenates old blood stem cells in mice.
- CHIP is found in more than 10% of people over 70 and is associated with higher risk of blood cancer, overall mortality and cardiovascular disease.
- In mice, the falling birth of new neurons in the hippocampus is linked to cognitive decline, and factors in old blood reduce it.
- Four factors (Oct4, Sox2, Klf4, c-Myc: OSKM) turn an adult cell back into a pluripotent stem cell (iPS).
- Reprogramming cells from centenarians erases several aging marks in vitro.
- Continuous OSKM expression in mice causes teratomas.
- Intermittent OSKM induction in progeroid mice improves aging traits and extends their life.
- In mouse eyes, OSK (without c-Myc) restores vision after optic nerve injury and in old animals, in a way that depends on DNA demethylation.
- Long-term partial reprogramming in normal old mice changes molecular aging markers without tumours detected in the study.
- Transient reprogramming "up to the maturation phase" rejuvenates human fibroblasts by about 30 years on epigenetic and transcriptomic clocks.
- Human cells have been reprogrammed into iPS cells with small molecules alone, opening the way to non-genetic approaches.
- In a phase I/II trial, allogeneic mesenchymal stem cell infusions for frailty had acceptable safety and signs of functional improvement (small sample).
- In heterochronic parabiosis, young blood restores muscle and liver stem cell activity in old mice.
- Old blood reduces new neuron birth and cognition in young mice; the chemokine CCL11 (eotaxin) is one culprit.
- Injecting only young plasma improves synaptic plasticity and memory in old mice.
- Young blood factors rejuvenate brain blood vessels in old mice.
- A single blood exchange shows that the inhibiting effect of old blood is fast and strong, often stronger than the benefit of young blood.
- Diluting old plasma with a saline-albumin solution rejuvenates several tissues in mice.
- Contrary to its claimed rejuvenating role, GDF11 was found to rise with age and inhibit muscle regeneration; the topic remains controversial.
- Umbilical cord plasma proteins (TIMP2) improve hippocampal function in old mice.
- The liver enzyme GPLD1 carries the brain benefits of exercise and improves cognition in old mice.
- Loss of Klotho in mice causes a syndrome resembling aging.
- Local inflammation in the hypothalamus (IKK-beta/NF-kB) speeds up whole-body aging in mice, and blocking it extends lifespan.
- Hypothalamic stem cells slow aging partly through microRNAs carried in exosomes.
- The SASP of senescent cells makes their neighbours senescent (paracrine senescence), orchestrated by the inflammasome.
- Transplanting a few senescent cells into a young mouse causes lasting physical dysfunction; D+Q improves physical function and survival.
- In C. elegans, collagen remodelling is required for longevity driven by the insulin/IGF-1 pathway.
- In the AMBAR phase IIb/III trial, plasma exchange with albumin slowed decline in moderate Alzheimer on some outcomes, with mixed results.
- In the PLASMA phase I trial, young plasma infusion in Alzheimer was safe and feasible, with no proven efficacy (small sample).
- With age the body keeps up a low but permanent inflammation without infection or injury ("inflammaging"), while the immune system becomes less effective (immunosenescence).
- Build-up of damaged molecules activates the NLRP3 inflammasome; removing NLRP3 in mice reduces systemic inflammation and age-related functional decline.
- DNA leaking from the nucleus or mitochondria activates cGAS-STING, which sustains age-related inflammation and neurodegeneration; blocking STING improves cognitive and physical function in old mice.
- Clonal hematopoiesis (mutations in DNMT3A, TET2, ASXL1, JAK2) affects more than 10% of people over 70 and raises the risk of blood cancer and death.
- CHIP roughly doubles the risk of coronary heart disease.
- TET2-deficient macrophages make more IL-1beta through NLRP3, speeding up atherosclerosis in mice.
- Inherited genetic variants predispose to CHIP.
- T cells with failing mitochondria are enough to trigger systemic inflammation and premature multi-organ senescence in mice.
- Old macrophages with metabolism disturbed by PGE2 sustain brain inflammation; restoring their metabolism (EP2 blockade) reverses cognitive decline in mice.
- Chronic inflammation is a shared risk factor for most age-related diseases, including cardiovascular disease.
- An inflammatory clock (iAge) built by deep learning on blood cytokines tracks multimorbidity, immunosenescence and frailty.
- In the CANTOS phase III trial, canakinumab (anti-IL-1beta) cut cardiovascular events by 15% in post-heart-attack patients with high CRP, but increased fatal infections.
- In the COLCOT phase III trial, low-dose colchicine reduced ischemic events after a heart attack.
- In the LoDoCo2 phase III trial, low-dose colchicine reduced cardiovascular events in chronic coronary disease; it was approved by the FDA in 2023 for cardiovascular prevention.
- In the 2-year randomized CALERIE trial, moderate caloric restriction lowered inflammatory markers without impairing immunity.
- In a phase IIa trial, mTORC1 inhibitors improved vaccine response and reduced infections in older people.
- In an open pilot trial (14 patients with pulmonary fibrosis), D+Q improved physical function and was feasible.
- Metformin has been proposed (TAME project) to target aging itself, through metabolism and inflammation; no results yet.
- In older Irish people, gut microbiome composition follows place of residence and diet; care-home residents with less varied diets have less diverse microbiomes, linked to more frailty and inflammation.
- In over 9,000 people, the microbiome becomes increasingly unique with age in healthy people, and this pattern predicts survival; it is absent in less healthy people.
- In mice, age-related dysbiosis increases gut permeability; bacterial products enter the blood and trigger systemic inflammation, and germ-free mice do not show this age-related rise.
- Some gut bacteria turn choline and carnitine into TMA, converted by the liver into TMAO, which promotes atherosclerosis in mice.
- In humans, high TMAO is associated with more cardiovascular events.
- Japanese centenarians have microbiomes enriched in pathways producing particular bile acids (such as isoallo-lithocholic acid) that inhibit pathogenic bacteria.
- Short-chain fatty acids (butyrate) made from fibre feed the gut wall and calm inflammation.
- Centenarians have microbiomes enriched in bacteria considered beneficial (Akkermansia, Bifidobacterium, Christensenellaceae).
- Urolithin A, made by gut bacteria from ellagitannins (pomegranate, nuts), activates mitophagy.
- Part of the antidiabetic effect of metformin goes through the gut microbiome.
- Metformin extends worm lifespan by changing the metabolism of its bacteria (folate and methionine).
- Transplanting gut microbes from young to old killifish extends lifespan.
- Fecal microbiota transplantation extends healthspan and lifespan of progeroid mice (Akkermansia involved).
- Young-to-old FMT reverses aging markers in the gut, retina and brain of mice.
- In the 1-year randomized NU-AGE trial (over 600 older people), a Mediterranean diet shifted the microbiome towards bacteria linked to less frailty, better cognition and less inflammation.
- In a 10-week randomized trial (36 people), fermented foods increased microbial diversity and lowered inflammatory markers.
- In a pilot trial (32 overweight people), pasteurized Akkermansia muciniphila improved insulin sensitivity and was safe.
- In phase I and II trials, urolithin A was safe and improved muscle endurance in older people, but the primary walking outcome was not met.
- In a randomized trial, one donor-feces infusion cured 81% of recurrent C. difficile infections versus 31% with vancomycin alone; FMT is approved for this infection, not for aging.
- Most major diseases (cancer, heart disease, Alzheimer, type 2 diabetes) rest on the same aging mechanisms, so acting on aging itself could delay several diseases at once.
- In the 2-year randomized CALERIE trial, caloric restriction in healthy non-obese adults improved cardiometabolic risk factors.
- In humans, low-dose rapamycin is well tolerated with modest effects.
- Metformin reduces the benefits of exercise in older people.
- A frailty index counts the share of health deficits a person has; it serves as a proxy measure of aging.
- In 2013, López-Otín and colleagues proposed 9 hallmarks of aging, grouped as primary, antagonistic and integrative.
- The 2023 update lists 12 hallmarks, adding disabled macroautophagy, chronic inflammation and dysbiosis.
- In adult humans, the death rate rises exponentially with age (Gompertz law), doubling roughly every 8 years; rhesus monkeys have a similar doubling time but higher mortality at all ages.
- A comparison of 46 species shows very diverse mortality and fertility trajectories, including mortality that stays flat or falls with age.
- Antagonistic pleiotropy: the same gene variant can help early in life (growth, fertility) and harm late, so selection favours it.
- Disposable soma: limited resources are split between reproduction and body maintenance, so maintenance stays imperfect.
- Harman proposed that aging comes from cumulative damage by free radicals from oxidative metabolism; antioxidant trials in humans did not extend life.
- Blagosklonny proposes that aging is driven mainly by growth programs (notably mTOR) that keep running after development, causing cellular hyperfunction; the theory predicted that rapamycin would slow aging.
- The information theory of aging holds that loss of epigenetic information is the main cause; the ICE mouse, with DNA breaks but no mutations, shows accelerated aging.
- Epigenetic clocks evolved from predicting calendar age (Horvath, Hannum) to predicting disease and death (PhenoAge, GrimAge) and measuring the pace of aging (DunedinPACE).
- Technical replicates of the same sample can differ by several years on some epigenetic clocks; principal-component versions improve reliability.
- No aging biomarker is validated as a regulatory surrogate endpoint; multi-omic approaches with long-term validation are recommended.
- A standard procedure exists to build a frailty index from a list of deficits.
- A clock trained on 2,897 plasma proteins in about 45,000 UK Biobank participants predicts mortality and common age-related diseases, and holds in Chinese and Finnish cohorts.
- Organ-specific aging signatures in the plasma proteome track health and disease.
- Fourteen blood metabolites measured by NMR are associated with all-cause mortality in 44,168 people.
- SENS proposes to periodically repair seven categories of accumulated damage instead of understanding all of metabolism.
- Health can be defined positively by eight hallmarks grouped in three domains (spatial compartmentalisation, maintenance of homeostasis, adequate responses to stress).
- The hallmarks framework lacks a causal hierarchy and is biased towards molecular damage, according to a critique by Gems and de Magalhães.